Information Technology Services
Compare Stocks
5 / 10Stock Comparison
DMRC vs CGNT vs VRNS vs NICE vs MSFT
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Infrastructure
Software - Infrastructure
Software - Application
Software - Infrastructure
DMRC vs CGNT vs VRNS vs NICE vs MSFT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Information Technology Services | Software - Infrastructure | Software - Infrastructure | Software - Application | Software - Infrastructure |
| Market Cap | $205M | $801M | $3.35B | $5.62B | $3.08T |
| Revenue (TTM) | $34M | $377M | $660M | $3.01B | $318.27B |
| Net Income (TTM) | $-32M | $-5M | $-137M | $529M | $125.22B |
| Gross Margin | 61.6% | 70.9% | 78.1% | 65.8% | 68.3% |
| Operating Margin | -94.4% | 0.9% | -21.9% | 20.7% | 46.8% |
| Forward P/E | — | 47.4x | 241.0x | 8.4x | 24.8x |
| Total Debt | $4M | $36M | $572M | $164M | $112.18B |
| Cash & Equiv. | $10M | $113M | $202M | $379M | $30.24B |
DMRC vs CGNT vs VRNS vs NICE vs MSFT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Digimarc Corporation (DMRC) | 100 | 25.6 | -74.4% |
| Cognyte Software Lt… (CGNT) | 100 | 38.5 | -61.5% |
| Varonis Systems, In… (VRNS) | 100 | 46.6 | -53.4% |
| NICE Ltd. (NICE) | 100 | 40.4 | -59.6% |
| Microsoft Corporati… (MSFT) | 100 | 178.6 | +78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DMRC vs CGNT vs VRNS vs NICE vs MSFT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DMRC lags the leaders in this set but could rank higher in a more targeted comparison.
CGNT ranks third and is worth considering specifically for momentum.
- +13.7% vs NICE's -43.4%
Among these 5 stocks, VRNS doesn't own a clear edge in any measured category.
NICE is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.
- Lower volatility, beta 0.48, Low D/E 4.2%, current ratio 1.55x
- PEG 0.32 vs MSFT's 1.32
- Beta 0.48, current ratio 1.55x
- Lower P/E (8.4x vs 24.8x), PEG 0.32 vs 1.32
MSFT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 19 yrs, beta 0.85, yield 0.8%
- Rev growth 14.9%, EPS growth 15.6%, 3Y rev CAGR 12.4%
- 7.8% 10Y total return vs VRNS's 315.3%
- 14.9% revenue growth vs DMRC's -11.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.9% revenue growth vs DMRC's -11.7% | |
| Value | Lower P/E (8.4x vs 24.8x), PEG 0.32 vs 1.32 | |
| Quality / Margins | 39.3% margin vs DMRC's -95.3% | |
| Stability / Safety | Beta 0.48 vs DMRC's 2.42, lower leverage | |
| Dividends | 0.8% yield; 19-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +13.7% vs NICE's -43.4% | |
| Efficiency (ROA) | 19.2% ROA vs DMRC's -54.8%, ROIC 24.9% vs -53.6% |
DMRC vs CGNT vs VRNS vs NICE vs MSFT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DMRC vs CGNT vs VRNS vs NICE vs MSFT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MSFT leads in 3 of 6 categories
NICE leads 1 • CGNT leads 1 • DMRC leads 0 • VRNS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MSFT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MSFT is the larger business by revenue, generating $318.3B annually — 9385.0x DMRC's $34M. MSFT is the more profitable business, keeping 39.3% of every revenue dollar as net income compared to DMRC's -95.3%. On growth, VRNS holds the edge at +26.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $34M | $377M | $660M | $3.0B | $318.3B |
| EBITDAEarnings before interest/tax | -$27M | $16M | -$135M | $841M | $192.6B |
| Net IncomeAfter-tax profit | -$32M | -$5M | -$137M | $529M | $125.2B |
| Free Cash FlowCash after capex | -$12M | $11M | $120M | $569M | $72.9B |
| Gross MarginGross profit ÷ Revenue | +61.6% | +70.9% | +78.1% | +65.8% | +68.3% |
| Operating MarginEBIT ÷ Revenue | -94.4% | +0.9% | -21.9% | +20.7% | +46.8% |
| Net MarginNet income ÷ Revenue | -95.3% | -1.2% | -20.7% | +17.6% | +39.3% |
| FCF MarginFCF ÷ Revenue | -36.8% | +3.0% | +18.1% | +18.9% | +22.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.9% | +15.5% | +26.9% | +9.5% | +18.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +52.5% | +173.6% | 0.0% | -61.7% | +23.4% |
Valuation Metrics
NICE leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 9.6x trailing earnings, NICE trades at a 68% valuation discount to MSFT's 30.4x P/E. Adjusting for growth (PEG ratio), NICE offers better value at 0.36x vs MSFT's 1.62x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $205M | $801M | $3.4B | $5.6B | $3.08T |
| Enterprise ValueMkt cap + debt − cash | $199M | $723M | $3.7B | $5.4B | $3.17T |
| Trailing P/EPrice ÷ TTM EPS | -6.28x | -65.35x | -25.25x | 9.59x | 30.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 47.40x | 240.96x | 8.38x | 24.77x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.36x | 1.62x |
| EV / EBITDAEnterprise value multiple | — | 84.84x | — | 6.40x | 19.46x |
| Price / SalesMarket cap ÷ Revenue | 6.04x | 2.28x | 5.37x | 1.91x | 10.94x |
| Price / BookPrice ÷ Book value/share | 5.04x | 3.67x | 6.16x | 1.51x | 9.02x |
| Price / FCFMarket cap ÷ FCF | — | 23.83x | 24.86x | 7.99x | 43.06x |
Profitability & Efficiency
MSFT leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MSFT delivers a 33.1% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-73 for DMRC. NICE carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRNS's 0.96x. On the Piotroski fundamental quality scale (0–9), NICE scores 7/9 vs DMRC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -72.6% | -2.0% | -27.4% | +14.0% | +33.1% |
| ROA (TTM)Return on assets | -54.8% | -0.9% | -8.2% | +10.3% | +19.2% |
| ROICReturn on invested capital | -53.6% | -2.5% | -11.0% | +13.2% | +24.9% |
| ROCEReturn on capital employed | -57.6% | -1.8% | -14.0% | +16.1% | +29.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 5 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.11x | 0.16x | 0.96x | 0.04x | 0.33x |
| Net DebtTotal debt minus cash | -$6M | -$77M | $369M | -$216M | $81.9B |
| Cash & Equiv.Liquid assets | $10M | $113M | $202M | $379M | $30.2B |
| Total DebtShort + long-term debt | $4M | $36M | $572M | $164M | $112.2B |
| Interest CoverageEBIT ÷ Interest expense | — | 21.71x | -9.01x | — | 55.65x |
Total Returns (Dividends Reinvested)
CGNT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MSFT five years ago would be worth $17,377 today (with dividends reinvested), compared to $3,261 for DMRC. Over the past 12 months, CGNT leads with a +13.7% total return vs NICE's -43.4%. The 3-year compound annual growth rate (CAGR) favors CGNT at 37.2% vs DMRC's -22.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +48.1% | +24.8% | -11.0% | -17.2% | -12.0% |
| 1-Year ReturnPast 12 months | -30.3% | +13.7% | -37.3% | -43.4% | -4.5% |
| 3-Year ReturnCumulative with dividends | -52.7% | +158.4% | +23.0% | -50.8% | +37.6% |
| 5-Year ReturnCumulative with dividends | -67.4% | -53.9% | -37.2% | -59.3% | +73.8% |
| 10-Year ReturnCumulative with dividends | -67.6% | -60.3% | +315.3% | +46.1% | +776.0% |
| CAGR (3Y)Annualised 3-year return | -22.1% | +37.2% | +7.2% | -21.1% | +11.2% |
Risk & Volatility
Evenly matched — CGNT and NICE each lead in 1 of 2 comparable metrics.
Risk & Volatility
NICE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than DMRC's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGNT currently trades 95.3% from its 52-week high vs VRNS's 44.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.42x | 1.28x | 0.94x | 0.48x | 0.85x |
| 52-Week HighHighest price in past year | $14.64 | $11.66 | $63.90 | $180.61 | $555.45 |
| 52-Week LowLowest price in past year | $4.07 | $6.29 | $19.70 | $90.70 | $356.28 |
| % of 52W HighCurrent price vs 52-week peak | +63.9% | +95.3% | +44.6% | +51.3% | +74.7% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 70.3 | 70.0 | 40.1 | 57.9 |
| Avg Volume (50D)Average daily shares traded | 223K | 498K | 2.3M | 635K | 32.5M |
Analyst Outlook
MSFT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DMRC as "Buy", CGNT as "Hold", VRNS as "Buy", NICE as "Buy", MSFT as "Buy". Consensus price targets imply 156.4% upside for DMRC (target: $24) vs -3.2% for CGNT (target: $11). MSFT is the only dividend payer here at 0.78% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $24.00 | $10.75 | $36.00 | $148.38 | $556.88 |
| # AnalystsCovering analysts | 8 | 5 | 34 | 23 | 81 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +0.8% |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | 0 | 19 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.23 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.4% | +0.7% | +3.4% | +8.8% | +0.6% |
MSFT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NICE leads in 1 (Valuation Metrics). 1 tied.
DMRC vs CGNT vs VRNS vs NICE vs MSFT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DMRC or CGNT or VRNS or NICE or MSFT a better buy right now?
For growth investors, Microsoft Corporation (MSFT) is the stronger pick with 14.
9% revenue growth year-over-year, versus -11. 7% for Digimarc Corporation (DMRC). NICE Ltd. (NICE) offers the better valuation at 9. 6x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Digimarc Corporation (DMRC) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DMRC or CGNT or VRNS or NICE or MSFT?
On trailing P/E, NICE Ltd.
(NICE) is the cheapest at 9. 6x versus Microsoft Corporation at 30. 4x. On forward P/E, NICE Ltd. is actually cheaper at 8. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: NICE Ltd. wins at 0. 32x versus Microsoft Corporation's 1. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — DMRC or CGNT or VRNS or NICE or MSFT?
Over the past 5 years, Microsoft Corporation (MSFT) delivered a total return of +73.
8%, compared to -67. 4% for Digimarc Corporation (DMRC). Over 10 years, the gap is even starker: MSFT returned +776. 0% versus DMRC's -67. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DMRC or CGNT or VRNS or NICE or MSFT?
By beta (market sensitivity over 5 years), NICE Ltd.
(NICE) is the lower-risk stock at 0. 48β versus Digimarc Corporation's 2. 42β — meaning DMRC is approximately 403% more volatile than NICE relative to the S&P 500. On balance sheet safety, NICE Ltd. (NICE) carries a lower debt/equity ratio of 4% versus 96% for Varonis Systems, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DMRC or CGNT or VRNS or NICE or MSFT?
By revenue growth (latest reported year), Microsoft Corporation (MSFT) is pulling ahead at 14.
9% versus -11. 7% for Digimarc Corporation (DMRC). On earnings-per-share growth, the picture is similar: NICE Ltd. grew EPS 43. 0% year-over-year, compared to -31. 4% for Varonis Systems, Inc.. Over a 3-year CAGR, MSFT leads at 12. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DMRC or CGNT or VRNS or NICE or MSFT?
Microsoft Corporation (MSFT) is the more profitable company, earning 36.
1% net margin versus -95. 3% for Digimarc Corporation — meaning it keeps 36. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSFT leads at 45. 6% versus -94. 4% for DMRC. At the gross margin level — before operating expenses — VRNS leads at 79. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DMRC or CGNT or VRNS or NICE or MSFT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, NICE Ltd. (NICE) is the more undervalued stock at a PEG of 0. 32x versus Microsoft Corporation's 1. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, NICE Ltd. (NICE) trades at 8. 4x forward P/E versus 241. 0x for Varonis Systems, Inc. — 232. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DMRC: 156. 4% to $24. 00.
08Which pays a better dividend — DMRC or CGNT or VRNS or NICE or MSFT?
In this comparison, MSFT (0.
8% yield) pays a dividend. DMRC, CGNT, VRNS, NICE do not pay a meaningful dividend and should not be held primarily for income.
09Is DMRC or CGNT or VRNS or NICE or MSFT better for a retirement portfolio?
For long-horizon retirement investors, Microsoft Corporation (MSFT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
85), 0. 8% yield, +776. 0% 10Y return). Digimarc Corporation (DMRC) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MSFT: +776. 0%, DMRC: -67. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DMRC and CGNT and VRNS and NICE and MSFT?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DMRC is a small-cap quality compounder stock; CGNT is a small-cap quality compounder stock; VRNS is a small-cap quality compounder stock; NICE is a small-cap deep-value stock; MSFT is a mega-cap quality compounder stock. MSFT pays a dividend while DMRC, CGNT, VRNS, NICE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.